{"id":"W4410592778","doi":"10.1016/j.annonc.2025.04.006","title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen's University","funders":"Unicancer; Grifols; Ipsen; Japanese Society of Medical Oncology; PharmaMar; European Society for Medical Oncology; Amgen; Koninklijke Nederlandse Akademie van Wetenschappen; Relay Therapeutics; Seagen; Genentech; Veracyte; Astellas Pharma; Fondazione Beretta; Mersana Therapeutics; Medical Research Council; Les Laboratories Pierre Fabre; Celldex Therapeutics; Advanced Accelerator Applications; Regeneron Pharmaceuticals; Natera; AstraZeneca; Associazione Italiana di Oncologia Medica; Daiichi Sankyo Europe; LEO Pharma; Servier; Gilead Sciences; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; NeraCare; World Health Organization; Sanofi; Pfizer","keywords":"Medicine; Identification (biology); Scale (ratio); Medical physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003899321,0.0007161652,0.001726698,0.003486052,0.0002606209,0.001706673,0.00105324,0.0009094217,0.03729813],"category_scores_gemma":[0.03394489,0.000394933,0.002303367,0.003314336,0.0003582592,0.001462955,0.001547669,0.002005222,0.006908531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001111122,"about_ca_system_score_gemma":0.001279181,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003452772,"about_ca_topic_score_gemma":0.004296341,"domain_scores_codex":[0.9968671,0.001209388,0.0007463971,0.0001779171,0.0008557991,0.0001432903],"domain_scores_gemma":[0.9877323,0.00631655,0.00323742,0.0004035075,0.001870112,0.0004401681],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00523783,0.0005122491,0.1917785,0.005337947,0.003877158,0.0002627983,0.0003387924,0.008897088,0.000471689,0.01254136,0.5607753,0.2099692],"study_design_scores_gemma":[0.002529578,0.001362109,0.5709135,0.002485494,0.001891449,0.001509593,0.0004143067,0.01060935,0.001056305,0.03841597,0.3684404,0.000371938],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"dataset","genre_gemma":"methods","genre_scores_codex":[0.1517862,0.02333235,0.03644374,0.008211985,0.0009503633,0.01245993,0.6240362,0.006191527,0.1365878],"genre_scores_gemma":[0.6210508,0.0130314,0.07380082,0.004062789,0.0008458177,0.02604777,0.2249958,0.002325523,0.03383923],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.03729813,"threshold_uncertainty_score":0.1247746,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1205150739325094,"score_gpt":0.401125847362559,"score_spread":0.2806107734300495,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}